Tilvestamab (BGB149) is a first-in-class, fully humanized, therapeutic anti-AXL function-blocking monoclonal antibody, discovered and developed by BerGenBio. A Phase Ia study in healthy volunteers has been completed. Preclinical data have shown tilvestamab prevents AXL-mediated cell signalling in cancer models, reduces cell migration and invasion, and shows anti-tumor efficacy.
An international Phase Ib first-in-patient trial investigating tilvestamab (BGB149) is currently ongoing with the objective to confirm safety, tolerability and determine a recommended phase II dose for use in subsequent clinical trials.
ClinicalTrials.gov Identifier: NCT04893551
